IDERA PHARMACEUTICALS INC's ticker is IDRA and the CUSIP is 45168K405. A total of 33 filers reported holding IDERA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $31,000 | -44.6% | 82,472 | -32.5% | 0.00% | – |
| Q2 2022 | $56,000 | +100.0% | 122,238 | +151.7% | 0.00% | – |
| Q4 2021 | $28,000 | -79.1% | 48,568 | -56.4% | 0.00% | – |
| Q2 2021 | $134,000 | -77.9% | 111,383 | -76.1% | 0.00% | – |
| Q1 2021 | $605,000 | -54.9% | 465,644 | +27.5% | 0.00% | -100.0% |
| Q4 2020 | $1,341,000 | +148.8% | 365,325 | +45.0% | 0.00% | 0.0% |
| Q3 2020 | $539,000 | -50.5% | 251,972 | -58.5% | 0.00% | 0.0% |
| Q2 2020 | $1,088,000 | +66.1% | 607,850 | +22.5% | 0.00% | 0.0% |
| Q1 2020 | $655,000 | -32.0% | 496,070 | -6.2% | 0.00% | 0.0% |
| Q4 2019 | $963,000 | -64.6% | 529,058 | -43.8% | 0.00% | -75.0% |
| Q3 2019 | $2,722,000 | +6.4% | 942,136 | -1.7% | 0.00% | 0.0% |
| Q2 2019 | $2,559,000 | +66.7% | 958,570 | +59.2% | 0.00% | +100.0% |
| Q1 2019 | $1,535,000 | -8.0% | 602,028 | -0.1% | 0.00% | -33.3% |
| Q4 2018 | $1,669,000 | -57.7% | 602,639 | +36.1% | 0.00% | -40.0% |
| Q3 2018 | $3,945,000 | – | 442,723 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ABG Innovation Capital Partners III GP Ltd | 56,250 | $206,000 | 0.12% |
| Baker Brothers Advisors | 4,608,786 | $16,914,000 | 0.06% |
| Artal Group S.A. | 500,000 | $1,835,000 | 0.04% |
| HOLLENCREST CAPITAL MANAGEMENT | 90,000 | $331,000 | 0.04% |
| Spotlight Asset Group, Inc. | 21,500 | $79,000 | 0.03% |
| DCF Advisers, LLC | 18,755 | $69,000 | 0.03% |
| 683 Capital Management, LLC | 88,470 | $325,000 | 0.02% |
| Palo Alto Investors LP | 77,044 | $283,000 | 0.02% |
| Alpine Global Management, LLC | 13,966 | $51,000 | 0.01% |
| TCI Wealth Advisors, Inc. | 4,000 | $15,000 | 0.01% |